| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 620 | 698 | 853 | 564 | 571 | 551 | 617 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 627 | 445 | 435 | 454 | 537 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 222 | 259 | 226 | 118 | 137 | 97 | 80 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 34 % | 35 % | 25 % | 19 % | 22 % | 17 % | 13 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 36 | 51 | 44 | 16 | 17 | 12 | 12 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 154 | 117 | 46 | 66 | 29 | 8 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 4.02 | 3.16 | 1.28 | 1.94 | 0.96 | 0.51 |
Cohance Lifesciences
Cohance Lifesciences
424.80
-4.10
(-0.96%)
Market Cap
16,251.45 Cr
PE Ratio
109.25
Volume
2,90,937.00
Day High - Low
430.25 - 420.15
52W High-Low
1,121.15 - 266.70
There are 1 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
16,251.45 Cr
EPS
4.69
PE Ratio
109.25
PB Ratio
4.19
Book Value
102.24
EBITDA
397.52
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
14.38
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
Cohance Lifesciences management will attend Citi and ICICI Securities conferences in Mumbai on June 5 and June 9, 2026.
Cohance Lifesciences Limited will attend investor conferences in Mumbai and Hyderabad in May and June 2026. No unpublished price-sensitive information will be shared.
Cohance Lifesciences FY26 revenue fell 13% to INR 22.68 Bn; Q4 net profit at INR 195 Mn. Earnings call reveals segment revenues, one-time items, and H2 FY27 recovery outlook.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,788.50 | #1 4,29,121.06 | 37.31 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 44.37 | |
6,576.50 | 1,74,585.41 | 67.49 | 10,560.00 | 8.73 | 2,520 | 13.44 | 46.75 | |
4,368.50 | 1,47,849.89 | 68.30 | 13,753.00 | 19.18 | 2,028 | -26.91 | 50.11 | |
1,375.20 | 1,11,086.00 | 28.84 | 27,711.70 | -2.46 | 3,783 | -55.32 | 52.65 | |
1,076.60 | 1,08,331.15 | 21.16 | 26,719.70 | 13.65 | 5,242 | 7.82 | 68.91 | |
1,263.30 | 1,05,440.45 | 25.59 | 33,593.30 | -0.44 | 3,998 | -86.05 | 41.47 | |
2,261.20 | 1,03,346.61 | #1 19.21 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 45.17 | |
2,369.50 | 97,814.16 | 48.97 | 14,277.60 | 12.03 | 1,750 | 31.75 | 50.42 | |
1,440.40 | 83,658.67 | 23.70 | 33,384.70 | 3.21 | 3,376 | 1.99 | 48.90 | |
1,394.30 | 75,272.20 | 83.88 | 6,812.90 | #1 21.03 | 884 | 21.18 | 76.00 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
80.60 %
Net Income Growth
-51.98 %
Cash Flow Change
-19.62 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-50.01 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 | 5,730 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 2,263 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 | 1,796 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 173 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 | 562 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 | 32 |
| Total Equity & Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 | 5,730 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 | 646 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 | 1,050 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 | 3,911 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,873 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 | 38 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 359 | 288 |
| Financing Activities | 26 | 7 | -76 | -156 | -242 | -14 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % | 57.49 % | 57.49 % | 57.49 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % | 6.51 % | 6.02 % | 5.59 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % | 20.82 % | 21.57 % | 21.79 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % | 6.42 % | 6.76 % | 7.04 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % | 8.75 % | 8.16 % | 8.08 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 | 85,230 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 |  Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 691.30 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 537.60 | 355.05 |
| 12 May 2026 | Quarterly Result Announcement | NA | 12 May 2026 | 454.60 | 478.65 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1 day ago
1 day agoCompliances-Reg.24(A)-Annual Secretarial Compliance4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call TranscriptMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2026
May 15, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2026
May 12, 2026Outcome Of The Board MeetingMay 12, 2026
May 12, 2026Board Meeting Outcome for Outcome Of The Board MeetingMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 06, 2026
May 06, 2026Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31 2026.May 06, 2026
May 06, 2026Clarification On Movement In Price Of Equity SharesApr 30, 2026
Apr 30, 2026Clarification sought from Cohance Lifesciences LtdApr 29, 2026
Apr 29, 2026Brief Profile Of Mr. Umang Vohra Chairman And Group CEOApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 27, 2026
Apr 27, 2026Board Meeting Outcome for Outcome Of Board MeetingApr 27, 2026
Apr 27, 2026Clarification With Respect To Volume MovementApr 13, 2026
Apr 13, 2026Clarification sought from Cohance Lifesciences LtdApr 13, 2026
Apr 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2026
Apr 02, 2026Appointment of Company Secretary and Compliance OfficerMar 30, 2026
Mar 30, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 13, 2026
Mar 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2026
Mar 06, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 24, 2026
Feb 24, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Feb 20, 2026
Feb 20, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 20, 2026
Feb 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Feb 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2026
Feb 12, 2026Outcome Of Board MeetingFeb 12, 2026
Feb 12, 2026Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2026
Feb 12, 2026Cohance Lifesciences Limited Has Informed The Exchange About Additional Information On USFDA Announcement.Feb 06, 2026
Feb 06, 2026Cohance Lifesciences Limited Has Informed The Exchange About USFDA Announcement.Feb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerFeb 02, 2026
Feb 02, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 22, 2026
Jan 22, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJan 22, 2026
Jan 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 22, 2026
Jan 22, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 19, 2026
Jan 19, 2026Grant Of Stock OptionsJan 17, 2026
Jan 17, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Jan 05, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine-Months Ending December 31 2025Dec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 24, 2025
Dec 24, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 23, 2025
Dec 23, 2025Intimation Of Change In Website Address Of The CompanyDec 13, 2025
Dec 13, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 51.73
ATR(14)
Less Volatile 22.20
STOCH(9,6)
Neutral 48.80
STOCH RSI(14)
Neutral 20.06
MACD(12,26)
Bearish -5.51
ADX(14)
Strong Trend 32.21
UO(9)
Bearish 40.90
ROC(12)
Downtrend And Accelerating -3.66
WillR(14)
Neutral -54.81
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
